Biofrontera AG (B8FK)
XETRA Stock Exchange · Germany · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 3.120 |
|---|---|
| 52-week range | 2.210 – 5.100 |
| Return, 1 month / 3 months | −22.8% / +23.8% |
| Return, 1 year / 3 years | +16.9% / −71.8% |
| Trend | Uptrend |
| RSI (14) | 53 |
| Volatility (1 year) | 57.6% |
| Worst drawdown (1 year) | -28.2% |
| Average daily value traded | 0.01M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Biofrontera AG is a German pharmaceutical company focused on dermatology. It develops and markets topical treatments for skin conditions, most notably a light-activated gel used in photodynamic therapy for actinic keratosis, a precancerous skin lesion. The company also supplies the special lamp used to activate its treatment during therapy sessions. Its customers are dermatologists and clinics, mainly in Europe and the United States, and it is based in Leverkusen, Germany.
On this site Biofrontera AG appears as a stock on the XETRA Stock Exchange (Germany), code B8FK, with prices in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Biofrontera AG (B8FK) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 3.120 on 23 October 2026.
Its price-based Market X-Ray is 57 out of 100 (a fair price profile), ranking 293 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 16.9% and over the last three months it rose 23.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 72 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 20.8% | ||
| From 52-week high | -22.8% | ||
| Momentum | 88 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 23.8% | ||
| 6-month return | 23.8% | ||
| 12-month return, skipping the last month | 51.3% | ||
| Stability (higher is calmer) | 37 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 57.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -28.2% | ||
| Liquidity | 15 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M EUR | ||
| Zero-volume days | 1.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +1.6% |
|---|---|
| 1 month | −22.8% |
| 3 months | +23.8% |
| 6 months | +23.8% |
| 1 year | +16.9% |
| 3 years | −71.8% |
| 5 years | −94.2% |
Signals
| 50-day / 200-day average | 2.838 / 2.584 |
|---|---|
| Golden / death cross (60 days) | Golden, 22 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.240 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.